Who
Kyle Guse
Director
Company insider
Files Form 4 as: Director, Cerenome; CFO, Gen Counsel and Secretary, Atossa Therapeutics.
In numbers
- Trades disclosed
- 30
- Buys
- 1
- Sells
- 0
- Bought
- $3,400
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 4 Jun 2013
- Last trade
- 1 Oct 2026
- Last filed
- 1 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 1 Oct 2026 | CNSY CerenomeMedical Devices | SEC FORM 4 Code M | —921 at $0.00 | filing |
| 1 Oct 2026filed 1 Oct 2026 | CNSY Cerenomeoption or derivative · Medical Devices | SEC FORM 4 Code M | —921 at $0.00 | filing |
| 1 Jul 2026filed 1 Jul 2026 | Plus TherapeuticsMedical Devices | SEC FORM 4 Code M | —922 at $0.00 | filing |
| 1 Jul 2026filed 1 Jul 2026 | Plus Therapeuticsoption or derivative · Medical Devices | SEC FORM 4 Code M | —922 at $0.00 | filing |
| 1 Jul 2026filed 1 Jul 2026 | Plus Therapeuticsoption or derivative · Medical Devices | SEC FORM 4 Code M | —922 at $0.00 | filing |
| 1 Jul 2026filed 1 Jul 2026 | Plus TherapeuticsMedical Devices | SEC FORM 4 Code M | —922 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | Plus Therapeuticsoption or derivative · Medical Devices | SEC FORM 4 Code A | —3,686 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | Plus Therapeuticsoption or derivative · Medical Devices | SEC FORM 4 Code A | —3,686 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | Plus Therapeuticsoption or derivative · Medical Devices | SEC FORM 4 Code A | —3,686 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | Plus Therapeuticsoption or derivative · Medical Devices | SEC FORM 4 Code A | —3,686 at $0.00 | filing |
| 13 Aug 2025filed 15 Aug 2025 | Plus Therapeuticsoption or derivative · Medical Devices | SEC FORM 4 Code A | —297,794 at $0.00 | filing |
| 13 Aug 2025filed 15 Aug 2025 | Plus Therapeuticsoption or derivative · Medical Devices | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 2 Mar 2023filed 6 Mar 2023 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —557,900 at $0.00 | filing |
| 24 Feb 2022filed 28 Feb 2022 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —746,667 at $0.00 | filing |
| 14 May 2021filed 18 May 2021 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —850,000 at $0.00 | filing |
| 9 Apr 2020filed 13 Apr 2020 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —195,000 at $0.00 | filing |
| 9 Apr 2020filed 13 Apr 2020 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —395,000 at $0.00 | filing |
| 13 Jan 2019filed 15 Jan 2019 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —700,000 at $0.00 | filing |
| 13 Jan 2019filed 15 Jan 2019 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —800,000 at $0.00 | filing |
| 27 Jun 2018filed 29 Jun 2018 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —700,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.